Pityriasis rubra pilaris (PRP) is an uncommon cutaneous disease with disorder of keratinisation. Up to now, systemic retinoids like acitretin or isotretinoin seem to be the most effective therapeutic agents. However, no large trials on this rare disease have been published and no standardised treatment has been established so far. Recently, single case reports demonstrate beneficial effects of alitretinoin (9-cis retinoic acid) in patients with PRP. We performed a retrospective observational analysis of type I adult-onset patients with PRP (n = 5) treated with systemic alitretinoin in our department. Alitretinoin was highly effective in the treatment of PRP in 4 of 5 cases. PASI score was reduced significantly in the alitretinoin responders. We assume that alitretinoin could serve as an additional effective systemic treatment option for type I adult-onset PRP. Key words: retinoids, vitamin A; retinoic acid; alitretinoin; pityriasis rubra pilaris; psoriasis.

RESULTS

Clinical evaluation

Clinical evaluation was documented by photographs. In the absence of a severity assessment score for PRP and since PRP shows similar clinical features to psoriasis, PASI (Psoriasis Area and Severity Index) score was evaluated prospectively in the clinical setting before and under alitretinoin treatment. Statistical analysis was performed by paired t-test with significant differences determined as p < 0.05.

RESULTS

Five individuals were diagnosed with ‘classical’ type I adult-onset pityriasis rubra pilaris. Previous systemic or local treatments (see Table S1) were ineffective.
After exclusion of contraindications all 5 patients were treated with alitretinoin 30 mg p.o./day. Patients 1–4 showed convincing clinical response already after 4–8 weeks (Fig. 1, Fig. S1, Fig. S2). Accordingly, PASI score assessed in these alitretinoin responders was on average reduced significantly about 71% ($p=0.006$) after 4–8 weeks (Fig. 2a).

In one case (patient 1) alitretinoin treatment was terminated after 22 weeks (Fig. 1c) and the patient remained free of symptoms. Alitretinoin was well tolerated in all patients except patient 3 showing an increase of creatine kinase and transaminases up to 3-fold compared to the normal level after 22 weeks of treatment.

In patient 5 the existing PRP lesions showed only slight reduction after 13-week treatment with acitretin 30 mg/day. When medication was switched to alitretinoin 30 mg/day a rapid progression and occurrence of new PRP skin lesions were observed within 3 weeks (Fig. 2b, c). Again, therapy was changed back to acitretin but in a higher dosage (75 mg/day) leading to a clear but slow improvement of skin symptoms over 15 weeks (Fig. 2d).

**DISCUSSION**

Pityriasis rubra pilaris is a chronic, progressive and intractable disease diagnosed by explicit clinical features supplemented by microscopic pathology. Its therapy is very challenging and clinical response is often sobering. In this retrospective report we demonstrate 5 cases of PRP treated with systemic alitretinoin. We could demonstrate that alitretinoin 30 mg/day was highly effective in 4 of 5 cases when alitretinoin was applied to treat PRP for the first time. This observation is consistent with previous single PRP case reports (8–10).

The detailed mode of action of alitretinoin in PRP is unknown. Due to the histological and clinical overlap of PRP with psoriasis vulgaris, parallels have been drawn regarding the therapeutic options. Alitretinoin has been found to produce an anti-inflammatory response (11). *In vitro*, alitretinoin showed higher affinity to RAR than to RXR and inhibited production of nitric oxide and proinflammatory cytokines such as tumour necrosis factor (TNF)-α, interleukin (IL)-1β and IL-12p40 (11, 12). Accordingly, efficacy of TNF-α inhibitors and the blocking IL-12/IL-23 anti-p40 monoclonal antibody ustekinumab was also shown in PRP case reports (13–15). Hence, beneficial therapeutic effects of alitretinoin in PRP might possibly be due to suppression of TNF-α and IL-12/IL-23 cytokines.

Interestingly, alitretinoin treatment failed in patient 5 but a shift to high-dose acitretin lead to partial remission of PRP lesions. Therefore, we suggest that patients with PRP could benefit from higher retinoid dosage or a shift to another retinoid if the previously chosen retinoid therapy remains unsuccessful.

In conclusion, we showed in a retrospective setting within a small collective that alitretinoin is a promising therapy for treatment of type I adult-onset PRP.

*Fig. 1. Clinical appearance of patient 1 with initial squamous erythroderma and islands of non-involved skin ("nappes claires") on the trunk and palmoplantar hyperkeratosis with painful fissures (a) before, (b) after 4 weeks and (c) 22 weeks of systemic alitretinoin therapy (30 mg/day).*

*Acta Derm Venereol 95*
The authors declare no conflict of interest.

REFERENCES